Public, NASDAQ:TARG
NASDAQ Global Market
Targanta Therapeutics Corp (3TT.BE) latest rank by number of funds that dumped the company.
Date: Sun, 29 Jun 2008 19:15:25 GMT
Tags:
Targanta Therapeutics Corp (3TT.BE) latest rank by number of funds that dumped the company.
Mffais.com - Jun 29, 2008
Mffais.com - Jun 29, 2008
LONG BEACH ( Mffais . com ) - Targanta Therapeutics Corp ( 3TT.BE ) is number 3909 for all United States stocks ranked by number of funds that dumped the company.The total number of funds selling ...
EMEA Accepts Targanta's Oritavancin MAA for Review
Date: Thu, 26 Jun 2008 23:32:05 GMT
Tags:
EMEA Accepts Targanta's Oritavancin MAA for Review
RedOrbit - Jun 26, 2008
RedOrbit - Jun 26, 2008
Targanta Therapeutics has announced that the European Medicines Agency has accepted for review its marketing authorization application for oritavancin , the company's novel semi - synthetic lipoglycopeptide ...
Targanta Therapeutics up 21% after seeking marketing approval for antibiotic
Date: Thu, 26 Jun 2008 17:26:35 GMT
Tags:
Targanta Therapeutics up 21% after seeking marketing approval for antibiotic
SmallCapInvestor - Jun 26, 2008
SmallCapInvestor - Jun 26, 2008
Targanta Therapeutics Corporation ( Nasdaq : TARG ) shares shot up more than 21 % after the company announced Thursday it was seeking approval for marketing a broad - spectrum antibiotic in the ...
EMEA accepts Targanta's oritavancin MAA for review
Date: Thu, 26 Jun 2008 16:35:08 GMT
Tags:
EMEA accepts Targanta's oritavancin MAA for review
Trading Markets (press release) - Jun 26, 2008
Trading Markets (press release) - Jun 26, 2008
Jun 26 , 2008 ( Datamonitor via COMTEX ) - - TARG | Quote | Chart | News | PowerRating - - Targanta Therapeutics has announced that the European Medicines Agency has accepted for review its marketing ...
Targanta Therapeutics (TARG) Announces EMEA Accepts Review for Oritavancin
Date: Wed, 25 Jun 2008 11:48:47 GMT
Tags:
Targanta Therapeutics (TARG) Announces EMEA Accepts Review for Oritavancin
StreetInsider.com (subscription) - Jun 25, 2008
StreetInsider.com (subscription) - Jun 25, 2008
Targanta Therapeutics Corporation ( Nasdaq : TARG ) today announced that the European Medicines Agency has accepted for review its Marketing Authorization Application for oritavancin , Targanta's ...
Targanta's Oritavancin MAA Accepted for Review by EMEA (Business Wire)
Date: Wed, 25 Jun 2008 09:58:00 Etc/GMT
Tags:
CAMBRIDGE, Mass.----Targanta Therapeutics Corporation today announced that the European Medicines Agency has accepted for review its Marketing Authorization Application for oritavancin, Targantaâs novel semi-synthetic lipoglycopeptide antibiotic candidate with potent bactericidal activity against a broad spectrum of gram-positive bacteria.
Targanta Submits Marketing Authorization Application for Oritavancin (Business Wire)
Date: Mon, 9 Jun 2008 09:58:00 Etc/GMT
Tags:
CAMBRIDGE, Mass.----Targanta Therapeutics Corporation announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for its lead candidate, oritavancin, a novel semi-synthetic lipoglycopeptide antibiotic candidate with potent bactericidal activity against a broad spectrum of gram-positive bacteria.
TARGANTA THERAPEUTICS CORP. Financials (EDGAR Online Financials)
Date: Thu, 22 May 2008 13:27:52 Etc/GMT
Tags:
Targanta Completes Enrollment in Phase 2 Oritavancin Infrequent Dosing Study (Business Wire)
Date: Tue, 20 May 2008 11:58:00 Etc/GMT
Tags:
CAMBRIDGE, Mass.----Targanta Therapeutics Corporation today announced that enrollment has been completed in its Phase 2 trial investigating the safety and efficacy of oritavancin at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections , or SIMPLIFI.
TARGANTA THERAPEUTICS CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a (EDGAR Online)
Date: Tue, 13 May 2008 12:30:52 Etc/GMT
Tags: